Company Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2026 BST			5-day change	1st Jan Change
86.08 ^USD	+1.71%		+6.65%	+10.63%

05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
05-05	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, A First-In-Class, Oral Irf5 Degrader, At Digestive Disease Week	CI

Business description: Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâ€™s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the bodyâ€™s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Number of employees: 253

Sales by Activity: Kymera Therapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Pharmaceuticals	72.83M	46.83M	78.59M	47.07M	39.21M

See all business segments

Geographical breakdown of sales: Kymera Therapeutics, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	72.83M	46.83M	78.59M	47.07M	39.21M

See all geographic segments

Executive Committee: Kymera Therapeutics, Inc.

Manager	Title	Age	Since
Nello Mainolfi CEO	Chief Executive Officer	47	31/10/2019
Bruce Jacobs DFI	Director of Finance/CFO	56	14/07/2019
Jeremy Chadwick COO	Chief Operating Officer	63	21/05/2023
Vijay Sabesan CTO	Chief Tech/Sci/R&D Officer	53	05/12/2021
Jared Gollob CTO	Chief Tech/Sci/R&D Officer	62	31/08/2018

See KYMERA THERAPEUTICS, INC. governance

Composition of the Board of Directors: Kymera Therapeutics, Inc.

Director	Title	Age	Since
Bruce Booth CHM	Chairman	51	31/07/2017
Nello Mainolfi BRD	Director/Board Member	47	31/10/2019
Gorjan Hrustanovic BRD	Director/Board Member	37	29/02/2020
Jeffrey Albers BRD	Director/Board Member	54	30/06/2020
Pamela Esposito BRD	Director/Board Member	52	03/09/2020
Elena Ridloff BRD	Director/Board Member	46	11/03/2021
John Maraganore BRD	Director/Board Member	62	31/12/2021
Victor Sandor BRD	Director/Board Member	59	02/11/2022
Felix Baker BRD	Director/Board Member	57	27/03/2024

Composition of the Board of Directors

Shareholders: Kymera Therapeutics, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 10.94 %	8,928,574	10.94 %	744 M $
Baker Bros. Advisors LP 10.6 %	8,657,242	10.6 %	721 M $
Avoro Capital Advisor LLC 9.155 %	7,474,747	9.155 %	623 M $
T. Rowe Price International Ltd. 7.544 %	6,159,335	7.544 %	513 M $
BVF, Inc. 6.74 %	5,502,710	6.74 %	458 M $

List of KYMERA THERAPEUTICS, INC. shareholders

Company details: Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

500 North Beacon Street

02472, Watertown

http://www.kymeratx.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
KYMERA THERAPEUTICS, INC.	+1.71%	+6.65%	+186.27%	+202.67%	7.08B
LONZA GROUP AG	-0.66%	+0.79%	-17.41%	-14.63%	43.39B
BEONE MEDICINES AG	-1.54%	+6.21%	+34.54%	+27.33%	34.7B
REVOLUTION MEDICINES, INC.	-0.49%	+1.67%	+250.84%	+464.31%	30.15B
IQVIA HOLDINGS INC.	+0.04%	+13.27%	+19.95%	-4.98%	29.83B
CELLTRION, INC.	-2.02%	-1.05%	+30.59%	+28.20%	28.46B
ASCENDIS PHARMA A/S	-3.04%	+8.03%	-	-	14.74B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-6.96%	+0.55%	+203.99%	+4,495.82%	14.48B
IONIS PHARMACEUTICALS, INC.	-0.41%	+0.57%	+134.69%	+111.30%	12.51B
EUROFINS SCIENTIFIC SE	-0.64%	+0.54%	+5.32%	-3.32%	12.29B
Average	-1.40%	+3.72%	+94.31%	+589.63%	22.76B
Weighted average by Cap.	-1.32%	+3.75%	+72.79%	+389.17%